Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 2
1954 2
1955 1
1973 1
1974 2
1975 2
1977 4
1979 3
1980 1
1983 1
1984 1
1986 4
1987 1
1988 3
1989 2
1990 1
1991 2
1992 6
1994 1
1995 5
1996 1
1998 1
1999 2
2000 4
2001 1
2002 3
2004 2
2005 5
2006 5
2007 4
2008 2
2009 2
2010 2
2011 2
2013 1
2014 1
2015 2
2016 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

83 results
Results by year
Filters applied: . Clear all
Page 1
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX. Lewis Phillips GD, et al. Among authors: lutz rj. Cancer Res. 2008 Nov 15;68(22):9280-90. doi: 10.1158/0008-5472.CAN-08-1776. Cancer Res. 2008. PMID: 19010901 Free article.
The prenylation of proteins.
Sinensky M, Lutz RJ. Sinensky M, et al. Among authors: lutz rj. Bioessays. 1992 Jan;14(1):25-31. doi: 10.1002/bies.950140106. Bioessays. 1992. PMID: 1546978 Review.
Antibody-maytansinoid conjugates designed to bypass multidrug resistance.
Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, Erickson HK, Sun X, Wilhelm S, Ab O, Lai KC, Widdison WC, Kellogg B, Johnson H, Pinkas J, Lutz RJ, Singh R, Goldmacher VS, Chari RV. Kovtun YV, et al. Among authors: lutz rj. Cancer Res. 2010 Mar 15;70(6):2528-37. doi: 10.1158/0008-5472.CAN-09-3546. Epub 2010 Mar 2. Cancer Res. 2010. PMID: 20197459 Free article.
83 results